The invention generally relates to charged mass label compositions and methods of use thereof for detecting a target analyte in a sample. In certain aspects, the invention provides a charged mass label composition including an affinity reagent, and a mass label precursor bound to the affinity reagent. The mass label precursor includes a label binding unit and a mass label. The label binding unit reversibly binds the mass label to the affinity reagent. The mass label includes a charge unit and a mass label unit having a pre-defined mass-to-charge-value in a mass spectrum.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

One aspect of the present disclosure relates to an isolated mutant human estrogen receptor alpha (hER) that may be used in methods of drug discovery. The isolated mutant hER can include a DNA-binding domain (DBD), a ligand-binding domain (LBD), and an interface between the DBD and the LBD, wherein at least one tryptophan residue is mutated to a phenylalanine residue.

The present invention relates to a novel anti-C-KIT antibody or an antibody fragment thereof. In addition, the present invention relates to a composition for preventing or treating angiogenesis-related diseases comprising the anti-C-KIT antibody or an antibody fragment thereof, or a kit for diagnosing angiogenesis-related diseases.

Disclosed are compounds, for example, a compound of formula I, ##STR00001##
wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition for example, cancer, mediated by the ras gene.

The present disclosure provides micro-array devices for capturing cells in blood and methods of their use. In some aspects, a method for counting cells in a blood sample is provided, the method comprising applying a blood sample onto a CNT device; allowing cells in the blood sample to differentially settle on the CNT device, and identifying and counting cells of preselected type in the blood sample.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present disclosure provides diagnostic methods useful for predicting a patient's response to alvocidib and guiding a physician decision to administer alvocidib to the patient.

Embodiments disclosed herein provide in vitro methods for use in the culture and biochemical analysis of normal or malignant cells in autologous, allogeneic, and xenogeneic fluids and the biomarkers secreted from those cells over time and in response to various changing conditions. The methods disclosed herein provide a clinical diagnostic and research platform that provides for the study of fundamental mechanisms of cellular morphology, cellular growth kinetics, intracellular and intercellular oncogenesis, therapeutic drug mechanisms or action and efficacy, identification and use of novel biomarkers or biomarker panels.

Disclosed are compounds, for example, a compound of formula I, wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition for example, cancer, mediated by the ras gene.

##STR00001##